HCW Biologics Inc Cash Flow Conversion Efficiency
HCW Biologics Inc cash flow conversion efficiency. Based on the latest financial reports, HCW Biologics Inc (HCWB) has a cash flow conversion efficiency ratio of -0.534x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($7.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of HCW Biologics Inc (2019–2025)
Cash flow conversion efficiency of HCW Biologics Inc from 2019 to 2025. This chart illustrates how HCW Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HCWB live share price for real-time trading data and today's change.
HCW Biologics Inc Cash Flow Conversion Ratio Explained
HCW Biologics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
HCW Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HCW Biologics Inc ranked by their cash flow conversion efficiency. Also see market cap of HCW Biologics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Himalaya Energi Perkasa Tbk PT
JK:HADE
|
-0.012x |
|
Human Xtensions Ltd
TA:HUMX
|
-0.626x |
|
Literacy Capital PLC
LSE:BOOK
|
-0.006x |
|
Haoxi Health Technology Limited Class A Ordinary Shares
NASDAQ:HAO
|
-0.142x |
|
Celtic PLC
LSE:CCP
|
-0.038x |
|
Downing Renewables & Infrastructure Trust PLC
LSE:DORE
|
0.022x |
|
Martello Technologies Group Inc
V:MTLO
|
0.039x |
|
Sri Havisha Hospitality and Infrastructure Limited
NSE:HAVISHA
|
-0.024x |
Annual Cash Flow Conversion Efficiency for HCW Biologics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of HCW Biologics Inc from 2019 to 2025. Review HCW Biologics Inc (HCWB) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.76 Million | $-13.39 Million | -4.844x | -330.49% |
| 2024-12-31 | $-6.77 Million | $-14.23 Million | 2.101x | +225.65% |
| 2023-12-31 | $13.46 Million | $-22.51 Million | -1.672x | -502.70% |
| 2022-12-31 | $37.43 Million | $-10.39 Million | -0.277x | -29.43% |
| 2021-12-31 | $51.19 Million | $-10.98 Million | -0.214x | +70.41% |
| 2020-12-31 | $14.40 Million | $-10.43 Million | -0.725x | +3.61% |
| 2019-12-31 | $9.00 Million | $-6.77 Million | -0.752x | -- |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more